Pesquisa de medicamentos por nome

Muromonab-cd3 Intravenous e Febre

Resultado da verificação da interação do medicamento Muromonab-cd3 Intravenous com doença Febre quanto a segurança no uso em conjunto.

Resultado da verificação:

Muromonab-cd3 Intravenous <> Febre

Relevância: 23.07.2019 Revisor: Shkutko P.M., M.D., in

Na verificação da interação, conforme informações das fontes confiáveis como Drugs.com, Rxlist.com, Webmd.com, Medscape.com, foram identificadas as contra-indicações ou efeitos colaterais que podem prejudicar a saúde ou aumentar efeito negativo ao consumir o medicamento com esta doença concomitante.

Consumidor:

Muromonab-CD3 não deve ser administrado na presença de um corpo de temperatura de 100 graus F (38,7 ° C) ou superior. Spiking febre (a 107 graus F) associado com a Liberação de Citocinas Síndrome de ter ocorrido. Antipiréticos podem ser administrados para reduzir a temperatura corporal nesta definição.

Referências

Radhakrishnan J, Cohen DJ "Cytokine-release syndrome: general risk-factor modification-- preparation of high-risk patients for use of OKT3." Transplant Proc 25 (1993): 60-2
Doutrelepont JM, Abramowicz D, Borre B, Lemoine A, De Pauw L, Kinnaert P, Vereerstraeten P, Vanherweghem JL, Goldman M "Prophylactic OKT3: practical considerations for the prevention of first-dose reactions." Transplant Proc 25 (1993): 45-6
Shihab F, Barry JM, Bennett WM, Meyer MM, Norman DJ "Cytokine-related encephalopathy induced by OKT3: incidence and predisposing factors." Transplant Proc 25 (1993): 564-5
Todd PA, Brogden RN "Muromonab CD3. A review of its pharmacology and therapeutic potential." Drugs 37 (1989): 871-99
Hall KA, Dole EJ, Hunter GC, Zukoski CF, Putnam CW "Hyperpyrexia-related ventricular tachycardia during OKT3 induction therapy." Transplantation 54 (1992): 1112-3
Shield CF II, Kahana L, Pirsch J, et al "Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection." Transplantation 54 (1992): 164-6
Sgro C "Side-effects of a monoclonal antibody, muromonab CD3 orthoclone OKT3: bibliographic review." Toxicology 105 (1995): 23-9
Norman DJ, Kimball JA, Barry JM "Cytokine-release syndrome: differences between high and low doses of OKT3." Transplant Proc 25 (1993): 35-8
First MR, Schroeder TJ, Hariharan S, Weiskittel P "Reduction of the initial febrile response to OKT3 with indomethacin." Transplant Proc 25 (1993): 52-4
First MR, Schroeder TJ, Hariharan S, Alexander JW, Weiskittel P "The effect of indomethacin on the febrile response following OKT3 therapy." Transplantation 53 (1992): 91-4
"Product Information. Orthoclone OKT 3 (muromonab-CD3)." Ortho Pharmaceutical Corporation, Raritan, NJ.
Devault GA, Kohan DE, Nelson EW, Holman JM "The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3." Transplantation 57 (1994): 532-40
Jeyarajah DR, Thistlethwaite JR, Jr "General aspects of cytokine-release syndrome: timing and incidence of symptoms." Transplant Proc 25 (1993): 16-20
Chatenoud L "OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody." Transplant Proc 25 (1993): 47-51
Agarwal RK, Ostaszewski ML, Feld LG, Springate JE, Moxey-Mims MM, O'Neil KM "Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3." Transplant Proc 25 (1993): 2143-4